JP2008512491A5 - - Google Patents

Download PDF

Info

Publication number
JP2008512491A5
JP2008512491A5 JP2007531416A JP2007531416A JP2008512491A5 JP 2008512491 A5 JP2008512491 A5 JP 2008512491A5 JP 2007531416 A JP2007531416 A JP 2007531416A JP 2007531416 A JP2007531416 A JP 2007531416A JP 2008512491 A5 JP2008512491 A5 JP 2008512491A5
Authority
JP
Japan
Prior art keywords
composition
tumor cell
cell population
cells
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007531416A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008512491A (ja
Filing date
Publication date
Priority claimed from US10/937,658 external-priority patent/US20060057127A1/en
Application filed filed Critical
Publication of JP2008512491A publication Critical patent/JP2008512491A/ja
Publication of JP2008512491A5 publication Critical patent/JP2008512491A5/ja
Withdrawn legal-status Critical Current

Links

JP2007531416A 2004-09-10 2005-09-09 前立腺癌の処置のためのサイトカイン発現細胞ワクチン Withdrawn JP2008512491A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/937,658 US20060057127A1 (en) 2004-09-10 2004-09-10 Cytokine-expressing cellular vaccines for treatment of prostate cancer
PCT/US2005/032357 WO2006031703A1 (en) 2004-09-10 2005-09-09 Cytokine-expressing cellular vaccines for treatment of prostate cancer

Publications (2)

Publication Number Publication Date
JP2008512491A JP2008512491A (ja) 2008-04-24
JP2008512491A5 true JP2008512491A5 (https=) 2008-10-02

Family

ID=36034247

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007531416A Withdrawn JP2008512491A (ja) 2004-09-10 2005-09-09 前立腺癌の処置のためのサイトカイン発現細胞ワクチン

Country Status (6)

Country Link
US (1) US20060057127A1 (https=)
EP (1) EP1789082A4 (https=)
JP (1) JP2008512491A (https=)
CN (1) CN101076351A (https=)
CA (1) CA2577989A1 (https=)
WO (1) WO2006031703A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
WO2008013989A2 (en) 2006-07-27 2008-01-31 Cell Genesys, Inc. Methods and compositions for identifying a cellular immune response against prostate cancer
JP2010514422A (ja) * 2006-12-22 2010-05-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 新規taa変種に基づく新たな融合分子
CA2679664C (en) * 2007-03-02 2017-04-25 Cell Genesys, Inc. Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer
US8840881B2 (en) * 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
BR112012027745A2 (pt) 2010-04-27 2017-01-10 Univ Johns Hopkins método e composição imunogênica para tratamento de neoplásia
CA2877721A1 (en) 2012-06-27 2014-01-03 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
JP6445022B2 (ja) 2014-01-14 2018-12-26 ザ プロクター アンド ギャンブル カンパニー ヒトの皮膚の外観及び感触を改善するための多工程製品
US20150196464A1 (en) 2014-01-14 2015-07-16 The Procter & Gamble Company Cosmetic Composition
US9931285B2 (en) 2014-01-14 2018-04-03 The Procter & Gamble Company Multi-step product for improving the appearance and feel of human skin
US10206859B2 (en) 2014-07-29 2019-02-19 The Procter & Gamble Company Cosmetic composition
US10539566B2 (en) 2014-12-08 2020-01-21 Berg Llc Use of markers including filamin A in the diagnosis and treatment of prostate cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5098702A (en) * 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US6544771B1 (en) * 1987-12-11 2003-04-08 Cell Genesys, Inc. Retroviral gene therapy vectors and therapeutic methods based thereon
US5436146A (en) * 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US6133028A (en) * 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
ATE336587T1 (de) * 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
IL116816A (en) * 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6093570A (en) * 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6040183A (en) * 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6033674A (en) * 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US6277368B1 (en) * 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US6548286B1 (en) * 1997-04-14 2003-04-15 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant AAV product
ES2218994T3 (es) * 1998-02-02 2004-11-16 The Johns Hopkins University School Of Medicine Linea celular inmunomoduladora universal que expresa citocinas y composiciones relacionadas y procedimientos de fabricacion y uso.
EP1125133A1 (en) * 1998-11-03 2001-08-22 Cell Genesys, Inc. Novel cancer-associated antigens and methods of their identification

Similar Documents

Publication Publication Date Title
Wang et al. Oxygen‐deficient molybdenum oxide nanosensitizers for ultrasound‐enhanced cancer metalloimmunotherapy
JP2008512491A5 (https=)
DE602005015990D1 (de) Immunogene t-helfer epitope von menschlichen tumorantigenen und deren verwendung in immunotherapeutischen methoden
CY1107973T1 (el) Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων
Zhang et al. Combination of photothermal therapy with anti‐inflammation therapy attenuates the inflammation tumor microenvironment and weakens immunosuppression for enhancement antitumor treatment
ATE494303T1 (de) An humane leukozytenantigen-(hla-)klasse-i- oder ii-moleküle bindende tumorassoziierte peptide und damit im zusammenhang stehender impfstoff gegen krebs
JP2010516259A5 (https=)
JP2011525191A5 (https=)
WO2011113819A3 (en) Diagnosis and treatment of cancer based on avl9
ATE276758T1 (de) Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
CA2354046A1 (en) New cancer treatments
PT1744789E (pt) Partículas activáveis por raios x e/ou uv, respectiva preparação e utilização terapêutica ou diagnóstica
ATE389712T1 (de) Krebs immuntherapie mit semi-allogenen zellen
JP2012021028A5 (https=)
ATE525908T1 (de) Einstufiges schnellverfahren zurherstellung eines antigenbeladenen dendritenzellimpfstoffs aus vorstufen
IL180612A0 (en) Materials and methods for immune system stimulation
EP2385059A3 (en) Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
WO2010045573A3 (en) Tumor vaccine
AU2599002A (en) Fusion cells and cytokine compositions for treatment of disease
TR201818784T4 (tr) Selenyum İle Kombinasyon Halinde Aronia Sp.'nin Bir Ekstraktını İçeren Bağışık Uyarıcı Terkip
EP1487482A4 (en) DNA VACCINE AGAINST THE PROLIFERATION OF ENDOTHELIAL CELLS AND METHODS OF USE THEREOF
AR041086A1 (es) Vacuna
SI1530628T1 (sl) Postopek za proizvodnjo s temperaturo induciranih lizatov tumorskih celic za uporabo kot imunogenske spojine
WO2002053700A3 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
ATE521629T1 (de) Matrixmetalloproteinase-11-impfstoff